Effect of Metformin on Frailty in 12 Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-24

Study Completion Date

2021-12-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes

NCT03309007

PreDiabetes Aging

COMPLETED PHASE3

Pilot Study on Evaluating the Geroprotective Effect of Metformin

NCT06459310

Metformin Aging

RECRUITING PHASE2

Metformin in Longevity Study (MILES).

NCT02432287

Aging

COMPLETED PHASE4

Metformin and Longevity Genes in Prediabetes

NCT01765946

Insulin Resistance Prediabetes Aging +1 more

COMPLETED PHASE4

Antecedent Metabolic Health and Metformin Aging Study

NCT04264897

Aging Insulin Sensitivity Chronic Disease +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart disease is the number one cause of death in the United States and disproportionately affects older adults, underscoring the need to examine determinants of survivorship. Recognizing this gap, current guidelines lay emphasis to assess frailty, a key construct prevalent in elderly and known to impact their prognosis.Older persons are commonly frail, manifest hyperglycemia and their health span is truncated by illnesses during which physiological declines together with accumulation of additional deficits results in multimorbidity and functional dependence. High incidence of functional decline and stress hyperglycemia in patients with coronary artery disease (CAD) makes pharmacologic manipulation, an attractive strategy to improve frailty and reduce adverse cardiovascular outcomes. Metformin exerts its effect on health span as a calorie restriction-mimetic through inhibition of mitochondrial complex 1 and activation of activated protein kinase (AMP).This drug is safe and has been shown to prolong life in mammals. Metformin by reducing effects of cellular senescence and improving glycemic control may improve the functioning of older adults.

In CAD, cellular senescence and inflammation affect organ dysfunction through interference with tissue homeostasis and regeneration. The deleterious effect of senescence includes pro-inflammatory senescence-associated secretory phenotype (SASP). Normal biological function through alteration in cellular homeostasis and restoration of glycemic control may be achieved by metformin. The phenotypic manifestations of these changes are incompletely characterized as it is yet unknown whether cell-intrinsic regenerative mechanisms can be translated into clinical improvement in physical performance and whether it's chronic administration is safe in older adults. These major gaps in knowledge hinder utilization of metformin as an agent to promote cellular regeneration and to reduce the impact of cellular senescence.

Targeting frail individuals with high levels of inflammation and SASP factors would necessitate identification of predictors of improvement with metformin in tissue inflammation and function. A clinomics approach implementing simultaneous assessment of clinical impact coupled with serological profiling would provide enhanced understanding of the local and systemic impact mediated by metformin. Through correlation of molecular profiles with phenotypic expression changes, as proposed herein, investigators will enhance understanding of the regenerative impact of metformin and the basis for clinical improvement in the setting of senescence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging Inflammation Frailty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Arms Assigned interventions Placebo Comparator: Metformin Chronic metformin administration through augmentation of cellular regeneration and reduction of senescence will improve frailty and physical functioning as studied by the short physical performance battery (SPPB) test. Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score \<9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months.

Placebo comparator: Placebo Placebo will be compared to chronic metformin administration Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score \<9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin

Metformin 500mg tablet by mouth, every 6 to 8 hours for one year

Group Type EXPERIMENTAL

Metformin

Intervention Type DRUG

Oral metformin (up to 2gm) will be given in divided doses

Placebo

Placebo by mouth every 6 to 8 hours for one year

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type DRUG

Oral Placebo will be given in divided doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

Oral metformin (up to 2gm) will be given in divided doses

Intervention Type DRUG

Placebo

Oral Placebo will be given in divided doses

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 60 years
* Stable CAD
* Prediabetes (one of the following criteria should be met)

* Fasting plasma glucose: 100-126 mg/dL
* HbA1C: 5.7-6.4
* Frailty (Short Physical Performance Battery: Score \<9)
* Able to return for follow-up
* Written informed consent

Exclusion Criteria

* Pre-existing or new-onset diabetes
* Any active malignancy, hematological disorder, post organ transplant, immunocompromised
* Cancer requiring treatment in the past 3 years (other than non-melanoma skin cancer)
* Dementia \[mini mental state examination (MMSE \<20)\]
* Disability (need for assistance in \>2 of any six activities on Katz activities of daily living (ADL)46
* Prior stroke with disability
* Acute coronary syndrome \<3months or participating in cardiac rehabilitation
* Severe Parkinson's
* Hepatic insufficiency and/or chronic liver disease (cirrhosis)
* Chronic kidney disease (GFR \< 45 mL/min)
* Taking metformin for any indication
* Acute alcohol intoxication
* Known hypersensitivity to metformin hydrochloride
* Acute/chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No